Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,598 recruiting studies in this area right now.
By phase
- Not applicable9,786
- Phase 24,449
- Phase 12,736
- Phase 1/Phase 21,687
- Phase 31,397
- Phase 2/Phase 3280
- Phase 4263
Top conditions
- Breast Cancer1,227
- Cancer661
- Prostate Cancer654
- Colorectal Cancer491
- Lung Cancer424
- Ovarian Cancer338
- Multiple Myeloma332
- Gastric Cancer296
- Acute Myeloid Leukemia292
- Pancreatic Cancer290
- Hepatocellular Carcinoma283
- Solid Tumor257
- Advanced Solid Tumor255
- Cervical Cancer232
- Head and Neck Cancer227
- Endometrial Cancer206
- Advanced Solid Tumors193
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center450
- Fudan University313
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)285
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center147
- AstraZeneca134
- University Health Network, Toronto125
Where studies are running
- California1,422
- Texas638
- Arizona513
- Florida448
- Alabama420
- New York409
- Massachusetts343
- Maryland329
- New Jersey269
- Pennsylvania241
Recruiting studies20,598 total
- NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT06204406Recruiting
Kidney-sparing treatment for upper tract urothelial cancer
This study looks at how well patients do when they have kidney-sparing treatment (instead of complete kidney removal) for upper tract urothelial carcinoma. It helps doctors understand which patients can safely avoid losing their kidney.
Shanghai, Shanghai MunicipalityAges 18–90 - NCT06825494RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+ - NCT06418061RecruitingPhase 1
Testing IBI3005 for advanced solid tumors
This trial tests an experimental drug called IBI3005 for people whose solid tumors (cancers that form lumps) have continued to grow despite treatment with a specific targeted therapy (EGFR TKI). The goal is to see if IBI3005 can help when other treatments have stopped working.
Jinan, ShandongAges 18 years+ - NCT06406426RecruitingPhase 2
New drug combo for advanced stomach cancer after first treatment fails
This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07311772RecruitingPhase 3
Testing houyanqing liquid for mouth sores during radiation
This trial tests a liquid medicine (houyanqing) to prevent or treat mouth sores caused by radiation therapy for nasopharyngeal cancer. You swish it in your mouth during radiation to see if it helps reduce pain and healing time.
Beijing, Beijing MunicipalityAges 18–75 - NCT06830850RecruitingPhase 1
Testing a new drug for metastatic prostate cancer
This trial tests a new drug, HRS-5041, for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to see if the drug is safe and can help control the cancer.
Sydney, New South WalesAges 18 years+ - NCT07310134RecruitingPhase 1
Study of ZX-8177 for advanced solid tumors
This trial tests a new oral drug (ZX-8177) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with standard options. The goal is to see if it is safe and helps control the disease.
ShanghaiAges 18 years+ - NCT06829355RecruitingPhase 2
Thymalfasin plus triple therapy for advanced colorectal cancer
This trial tests a combination of three drugs plus thymalfasin, an immune-boosting medicine, for people whose advanced colorectal cancer has not responded to at least two prior treatments. It's designed specifically for the common type of colorectal cancer (pMMR/MSS) to see if adding this immune therapy can help.
Beijing, ChinaAges 18–75 - NCT07690787RecruitingPhase 2
Study of JS207 for nasopharyngeal cancer
This trial tests a new drug, JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow. It's for people with nasopharyngeal cancer that has not spread too much, and who have not had certain prior treatments.
Hong KongAges 18 years+ - NCT06822998RecruitingEarly Phase 1
HF50 for HER-2 positive and low-expression advanced tumors
This trial tests a new drug, HF50, in people with advanced solid tumors that are HER-2 positive or have low HER-2 levels. It may be an option if standard treatments have stopped working or are not tolerated.
Chengdu, SichuanAges 18–75 - NCT06277791RecruitingPhase 2
Adebrelimab plus chemo before surgery for advanced oral cancer
This trial is testing a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (paclitaxel and carboplatin) given before surgery for advanced oral cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hubei, WuhanAges 18–75 - NCT06335420Recruiting
Can carrot juice prevent colon polyps from coming back?
This study tests whether drinking carrot juice every day can lower the chance that large colon polyps or early colon cancers will come back. Researchers want to see if the nutrients in carrot juice help protect the lining of the colon.
OdenseAges 18 years+ - NCT06212076RecruitingPhase 1/Phase 2
Testing IPG1094 for advanced solid tumors
This trial tests a new drug called IPG1094 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06221670RecruitingPhase 2
Toripalimab after surgery for high-risk early lung cancer
This trial tests whether giving a drug called Toripalimab after surgery can help prevent early-stage non-squamous non-small cell lung cancer from coming back. It is for people whose tumors have high-risk features and PD-L1 levels of at least 1%.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06440902RecruitingPhase 2
New treatments for RAS-changed colorectal cancer using blood tests
This study tests new treatment plans for people with metastatic colorectal cancer whose tumors originally had a RAS mutation but later show no RAS mutation in blood tests. The goal is to see if these treatment changes can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06820424RecruitingEarly Phase 1
CDH17-targeted CAR-T cells for advanced solid tumors
This trial tests a new type of immunotherapy that uses your own modified immune cells (CAR-T cells) to find and attack cancer cells that carry a specific marker called CDH17. It is for adults with advanced solid tumors that have CDH17 and who have run out of standard treatment options.
Kunming, YunnanAges 18–75 - NCT06230471RecruitingPhase 2
Pembrolizumab plus lenvatinib or chemo for advanced bile duct cancer
This study tests whether adding another drug (lenvatinib or chemotherapy) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for advanced bile duct or gallbladder cancer that has not been treated before. It aims to find a more effective first treatment option.
Beijing, Beijing MunicipalityAges 18–80 - NCT06816992RecruitingPhase 1
ORIC-114 with amivantamab for EGFR exon 20 insertion lung cancer
This trial tests an experimental pill (ORIC-114) combined with a targeted injection (amivantamab) for a specific type of non-small cell lung cancer that has an EGFR exon 20 insertion mutation. It aims to see if the combination shrinks tumors or delays growth.
New York, New YorkAges 18 years+ - NCT06816914RecruitingPhase 2
Perioperative chemo for resectable pancreatic cancer
This trial tests a combination of chemotherapy drugs (liposomal irinotecan with fluorouracil, leucovorin, and oxaliplatin) given before and after surgery for pancreatic cancer that can be fully removed. It aims to see if this approach improves outcomes for patients with stage I or II disease.
Kaohsiung CityAges 20–75 - NCT06430814Recruiting
Blood test to predict nerve damage from paclitaxel
This study looks at whether certain markers in your blood can predict nerve damage from paclitaxel chemotherapy. If you join, researchers will monitor your nerve health during treatment to better understand and possibly prevent side effects.
OdenseAges 18 years+ - NCT06104215RecruitingEarly Phase 1
BGT007H cells for advanced digestive cancer
This trial tests a new cell therapy called BGT007H for people with advanced digestive tract cancers (esophagus, stomach, pancreas, or colon) that have not responded to or stopped working after at least two prior treatments. The goal is to see if this therapy can help shrink tumors or slow the disease.
Xuzhou, JiangsuAges 18–70 - NCT06353854Recruiting
Study of biomarkers in MSI-high colorectal cancer patients on immunotherapy
This trial is studying people with a specific type of advanced colorectal cancer (MSI-high/dMMR) who are starting immunotherapy with pembrolizumab. The goal is to find out which markers in the tumor might predict whether the treatment works well.
BayonneAges 18 years+ - NCT06224257RecruitingPhase 2
Linperlisib for relapsed or refractory T-LGLL
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
Hefei, AnhuiAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,598 recruiting oncology studies from the U.S. registry right now, out of 31,285 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.